MOUNTAIN VIEW, Calif. – Genetic testing company 23andMe Inc. will comply with a Food and Drug Administration directive to stop providing access to health-related reports from its tests during a regulatory review.
The Mountain View, Calif., company said late Thursday that it will continue to provide ancestry-related information to customers and raw genetic data without interpretation. Those customers could receive additional, health-related information in the future, depending on whether the FDA grants marketing authorization.
Customers who bought kits since the FDA order came out late last month also will be eligible for refunds.
23andMe’s saliva-based test kit, launched more than five years ago, claims to tell customers if they are at risk for more than 250 diseases and health conditions. The company sells its tests online. Customers receive a small tube in the mail, which they return to the company with a saliva sample for DNA analysis.